CVAC - CureVac NV

https://www.curevac.com

Momentum: Bearish

Recent News

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Zacks Commentary • 2 months, 3 weeks ago • score: 0.53

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.

52W High

$5.72

52W Low

$2.37

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.53

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

5.39

Forward P/E (<15 better)

5.24

EV/EBITDA (<8 favorable)

2.86

EV/Revenue (<3 favorable)

1.34

P/S (TTM) (<3 favorable)

2.38

P/B (<3 favorable)

1.78

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

57.37%

Institutions (25–75% balanced)

6.49%

Shares Outstanding

225,173,000

Float

125,869,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

510,509,000

Gross Profit (TTM)

484,203,000

EPS (TTM)

1.00

Profit Margin (>10% good)

0.38%

Operating Margin (TTM) (higher better)

-49.59%

ROE (TTM) (>15% strong)

0.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.91

Momentum

Bearish momentum

Value

-0.0140

-0.0103

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025